Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Autolus Limited
Roswell Park Cancer Institute
Wake Forest University Health Sciences
Fondazione Italiana Linfomi - ETS
CRISPR Therapeutics
Emergent BioSolutions
Rutgers, The State University of New Jersey
Dana-Farber Cancer Institute
The First Affiliated Hospital with Nanjing Medical University
Beijing Boren Hospital
miRagen Therapeutics, Inc.
Brown University
Spectrum Pharmaceuticals, Inc
miRagen Therapeutics, Inc.
Fred Hutchinson Cancer Center
Yale University
Celgene
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
University of Rochester
National Cancer Institute (NCI)
Mundipharma Research Limited
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Nevada Cancer Institute
Rutgers, The State University of New Jersey